Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept's Liquid Biopsy Test in Immunotherapy
"Liquid biopsies have revolutionized oncology and precision medicine with the ability to obtain important biomarker information to identify patients for targeted therapy," said
"Immunotherapy has become an important treatment strategy for patients diagnosed with cancer and we believe that our unique liquid biopsy assay for PD-L1 offers a solution for rapid and non-invasive detection of this critical biomarker," said
About PD-L1 Biomarker Expression Using Liquid Biopsy
PD-L1 immunohistochemistry (IHC) on tumor tissue is an important predictive biomarker for anti-PD-1/anti-PD-L1 cancer immunotherapy. PD-L1 IHC is a companion diagnostic for the utilization of anti-PD-1 directed therapies in non-small cell lung cancer (NSCLC) and bladder cancer, and can predict response to immune checkpoint blockade. However, tissue biopsy is not always available or may be insufficient to accurately test for PD-L1 expression and biopsy samples may not reflect the actual PD-L1 expression of the tumor due to tumor heterogeneity. Given this heterogeneity and the risks inherent with tissue biopsy, the ability to detect tumor PD-L1 status with a simple blood draw would be a major advance in this field. In addition to minimizing patient risk from a tissue biopsy, a circulating biomarker assay can avoid biopsy
selection bias and provide a snapshot of the dynamic tumor landscape.
About
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to improve the
outcomes of patients diagnosed with cancer, the success of the
View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-and-uc-san-diego-medical-center-announce-clinical-study-collaboration-to-demonstrate-utility-of-biocepts-liquid-biopsy-test-in-immunotherapy-300562124.html
SOURCE
News Provided by Acquire Media